BioPharma Dive February 21, 2024
Iovance Biotherapeutics’ Amtagvi is the first marketed treatment that uses tumor-infiltrating lymphocytes, a technology long in development.
A long research journey has finally paid off for Iovance Biotherapeutics, which last week won Food and Drug Administration approval of the first cell therapy to treat advanced melanoma. The clearance could also open the door for a new type of cancer immunotherapy.
Iovance’s therapy, called Amtagvi, is built from a type of immune cells known as tumor-infiltrating lymphocytes, or TILs, which are collected directly from a tumor sample and fortified in a laboratory to better fight the cancer.
Academic researchers have studied TIL therapy for decades, but scientific and regulatory factors slowed the technology’s progress toward market, according to Jason Bock, head...
Today's Sponsors
Today's Sponsor